期刊
INTERNATIONAL JOURNAL OF HEMATOLOGY
卷 93, 期 5, 页码 571-577出版社
SPRINGER JAPAN KK
DOI: 10.1007/s12185-011-0803-1
关键词
Tumor necrosis factor; Graft-versus-host disease; Allogeneic; Bone marrow transplantation; Treatment; Prevention
类别
资金
- NCI NIH HHS [P01 CA039542] Funding Source: Medline
- NHLBI NIH HHS [R34 HL105776] Funding Source: Medline
Clinical graft-versus-host disease (GVHD) symptoms are the result of a complex set of interactions between cellular and soluble factors. One of the key soluble factors is the proinflammatory cytokine, TNF-alpha, which participates in the initiating events that culminate in GVHD as well as amplifies the disease process once established. The importance of TNF-alpha in this process has been supported by a series of clinical experiments demonstrating strong correlation between TNF receptor-1 levels and GVHD. TNF-alpha has both indirect effects, through activating and proliferation pathways of T cells, the main cellular effector of GVHD, and direct effects leading to apoptosis, on GVHD target tissues. Accordingly, TNF-alpha has been used as a therapeutic target in experimental GVHD prevention and treatment strategies with promising clinical results. TNF-alpha can be pharmacologically inhibited using soluble TNF receptors or monoclonal antibodies. The optimal dosing and duration of TNF inhibition to prevent or treat GVHD remains under investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据